Company news

Vera Therapeutics, Inc. (NASDAQ:VERA) news

Vera Therapeutics, Inc. news releases on 6ix. Latest, Aug 8, 2024: Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Vera Therapeutics, Inc. (NASDAQ:VERA) news

Press releases — page 2

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Vera Therapeutics Scheduled to Present at November Investor Conferences

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Vera Therapeutics Scheduled to Present at September Investor Conferences

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN

Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)

Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Vera Therapeutics to Present at Upcoming Investor Conferences

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidn...

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week...

Vera Therapeutics to Present at Upcoming Conferences in September 2022

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Vera Therapeutics to Present at Upcoming Conferences in May 2022